Democrats' Midterm Win Could Ease Headwinds For Drugmakers — Market Talk

What happened

Vontobel analyst Jean-Philippe Bertschy says Democratic control of both chambers of the U.S. Congress could make it less likely that Trump’s international drug-pricing deals become law, potentially easing a policy headwind for Swiss drugmakers. He also says Democrats’ focus on lowering prescription costs limits the case for a broadly positive sector view.

Confirmed

Global impact / market context

If the deals are less likely to become law, Swiss drugmakers could face less risk from that particular pricing policy. But pressure to lower prescription costs could still constrain revenue or profit per sale, so the political shift does not clearly remove the sector’s pricing challenges.

Analyst inference

The article frames the possible change as a reduction in policy risk, not a guaranteed improvement in drugmakers’ business. Swiss companies named include Roche, Novartis, Alcon and Sandoz, while the continued focus on cheaper prescriptions leaves potential pricing pressure in view.

Analyst inference

What to watch

1. Watch whether Democrats gain control of both the U.S. Senate and House, the political condition behind Bertschy’s view about the drug-pricing deals. Analyst inference
2. Watch for developments on whether the international drug-pricing deals are incorporated into law; the article says Democratic scrutiny could make that less likely. Analyst inference
3. Watch whether policy efforts to lower prescription costs translate into pricing pressure for Swiss drugmakers, which could offset any relief from reduced risk around the deals. Analyst inference

Evidence

• Original source link unavailable